Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 496

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

Open access
Mitry, E, Baudin, E, Ducreux, M, Sabourin, J-C, Rufié, P, Aparicio, T, Lasser, P, Elias, D, Duvillard, P, Schlumberger, M, Rougier, P·1999·British Journal of Cancer

Abstract

The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a combination of etoposide 100 mg m(-2) day(-1) for 3 days and cisplatin 100 mg m(-2) on day 1, given by 2-h intravenous infusion, administered every 21 days. Twelve patients had a well-differentiated and 41 a poorly differentiated neuroendocrine tumour. Toxicity of treatment was assessed in 50 patients and efficacy in 52 patients. Among the 11 patients with a well-differentiated tumour evaluable for tumoural response, only one (9.4%) had a partial response for 8.5 months. Forty-one patients with a poorly differentiated tumour showed an objective response rate of 41.5% (four complete and 13 partial responses); the median duration of response was 9.2 months, the median overall survival 15 months and the median progression-free survival 8.9 months. Haematological grade 3-4 toxicity was observed in 60% of the cases with one treatment-related death, digestive grade 3-4 toxicity in 40% and grade 3 alopecia was constant. No severe renal, hearing and neurological toxicities were observed (grade 1 in 6%, 14%, 72% respectively and no grade >1). We confirm that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus cisplatin combination. However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6690325

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 496

Metadata

Authors
Mitry, E., Baudin, E., Ducreux, M., Sabourin, J.-C., Rufié, P., Aparicio, T., Lasser, P., Elias, D., Duvillard, P., Schlumberger, M., & Rougier, P.
Venue
British Journal of Cancer
Published
1999-11-26
Volume
81
Issue
8
Pages
1351-1355
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1995681258
Cited by
496
References
16
FWCI
3.32
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. https://app.cochat.ai/papers/10.1038/sj.bjc.6690325
The paper
Mitry, E., Baudin, E., Ducreux, M., Sabourin, J.-C., Rufié, P., Aparicio, T., Lasser, P., Elias, D., Duvillard, P., Schlumberger, M., & Rougier, P. (1999). Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6690325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.